Bifidobacterium longum for Health & Longevity - Quick Reference Sheet

Bifidobacterium longum for Health & Longevity

Created on 08/04/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

A gut bacterium sold as a probiotic. Its most dependable effect is shifting the gut community and helpful acids, mainly while it is taken. Bowel comfort, regularity, and stress show moderate, sometimes conflicting benefits; immune, inflammation, and cholesterol effects are small; brain and longevity benefits stay unproven. Low-risk and low-cost; results depend on a well-tested strain and adequate fiber. (Full Review)

Protocol

Standard Dose
1–50 billion CFU/day
Many effective studies cluster around 1–10 billion CFU daily
Best Time of Day
With or before a meal
Food buffers stomach acid and improves survival
Dosing Frequency
Once daily
Continuous daily dosing is standard; splitting sometimes used at higher counts
Time to effect
Digestion & Regularity
1–2 weeks
When digestive and regularity changes often appear
Stress & Mood
4 weeks or longer
The point at which trials typically assess these outcomes
Immune Outcomes
4 weeks or longer
A fair trial lasts at least a month

Benefits

Contraindications
  • Severe immunocompromise
  • Critical illness (including intensive-care patients)
  • Central venous catheter
  • Short-bowel syndrome
  • Severe acute illness (e.g., acute pancreatitis)
Key Interactions
  • Antibiotics (amoxicillin, ciprofloxacin, clindamycin)
  • Antifungal and antiprotozoal agents (fluconazole, metronidazole, nitazoxanide)
  • Immunosuppressants and chemotherapy (corticosteroids, calcineurin inhibitors, cytotoxic chemotherapy)
  • Antacids and proton-pump inhibitors (omeprazole)

Risk & Side Effects

  • High: Transient digestive symptoms
  • Medium: Bloodstream infection in vulnerable individuals
  • Low: Symptom worsening in small intestinal bacterial overgrowth or histamine sensitivity; adverse outcomes when used during severe acute illness; product quality and contamination risks
  • Speculative: Transfer of antibiotic-resistance genes; D-lactic acidosis

Monitoring

Marker Target Why
hs-CRP < 1.0 mg/L Tracks body-wide inflammation the bacterium may modestly lower
Fasting glucose 75–90 mg/dL Gauges metabolic effects seen with some strains
LDL cholesterol < 100 mg/dL Captures the small lipid changes some trials report
Vitamin B12 500–900 pg/mL Bifidobacteria contribute to B-vitamin production in the gut

Cadence: Baseline, then about 8–12 weeks, then every 6–12 months

Qualitative Assessment

  • Bowel regularity and stool comfort
  • Perceived stress and mood
  • Energy and digestive wellbeing
  • Cognitive clarity